NAPRA has revised the listing with updated recommendations.
On July 26, 2022, NAPRA’s Board of Directors approved recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) regarding the scheduling of topical diclofenac diethylamine.
The National Drug Schedules have been amended as follows:
- Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16 per cent and less than or equal to 2.32 per cent for not more than seven days – in package sizes containing greater than 2.6g of diclofenac diethylamine be granted Schedule III status.
- Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16 per cent and less than or equal to 2.32 per cent for not more than seven days – in package sizes containing no more than 2.6g of diclofenac diethylamine be granted Unscheduled status.
- Diclofenac diethylamine – for human use – when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16 per cent for not more than seven days remain Unscheduled.
Registrants can stay up to date with NDS information by subscribing to their updates.
